Loss of Lean Body Mass as an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer.
about
The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensityDoes a laparoscopic approach attenuate the body weight loss and lean body mass loss observed in open distal gastrectomy for gastric cancer? a single-institution exploratory analysis of the JCOG 0912 phase III trial.Risk Factors for Poor Compliance with Adjuvant S-1 Chemotherapy for Gastric Cancer: A Multicenter Retrospective Study.Risk Factors for the Loss of Lean Body Mass After Gastrectomy for Gastric Cancer.Multi-institutional prospective feasibility study to explore tolerability and efficacy of oral nutritional supplements for patients with gastric cancer undergoing gastrectomy (CCOG1301).Randomized clinical trial comparing standard diet with perioperative oral immunonutrition in total gastrectomy for gastric cancer.Unplanned admission after gastrectomy as a consequence of fast-track surgery: a comparative risk analysis.Postoperative complications and weight loss following jejunostomy tube feeding after total gastrectomy for advanced adenocarcinomas.Clinical Outcomes of Gastric Cancer Patients Who Underwent Proximal or Total Gastrectomy: A Propensity Score-Matched Analysis.Quality of life and nutritional consequences after aboral pouch reconstruction following total gastrectomy for gastric cancer: randomized controlled trial CCG1101.Nutritional support for cancer patients: still a neglected right?Sarcopenia and Comorbidity in Gastric Cancer Surgery as a Useful Combined Factor to Predict Eventual Death from Other Causes.Protocol for enhanced recovery after surgery improves short-term outcomes for patients with gastric cancer: a randomized clinical trial.Postoperative Serum Albumin is a Potential Prognostic Factor for Older Patients with Gastric Cancer.Who Can Perform Adjuvant Chemotherapy Treatment for Gastric Cancer? A Multicenter Retrospective Overview of the Current Status in Korea
P2860
Q37605485-2832431E-C9E7-404A-A546-CB0058F2AFDFQ38721632-B1C03216-7BA3-45E7-8045-456846769898Q38728450-3EA1E554-9E73-4E42-929E-3D85F96D5366Q38921403-0AFE94AC-9287-4CC2-964D-07E6375B7B33Q39155159-1D54AADF-D3E0-4B6C-BF6F-17C20817E17DQ40387532-886F660E-C934-4405-BE46-D2BAED85407AQ40456486-73F4AC0A-32CB-455E-9FC9-791DB0492A1AQ41662359-6D102AB7-69DF-4CFB-8E0E-D5FA897BD4EDQ47618107-8129EA89-203C-40DD-9D77-3AEAFB02CC58Q47988914-CD1BFFFB-BC09-45B8-8477-1E1215FEA8C7Q48121516-984AC7AF-F38D-4446-9DAE-3915F187E90FQ50193948-DD0D509A-90E5-4846-A094-9AED398C5431Q53588958-AFCC1CA7-D8E3-4E9B-9018-3C95522EB1D3Q55301544-483D2965-1CD8-4047-A927-0D7E631403D8Q57125976-9EBE5A9E-00B0-4591-8FD9-4C87E6BE9EB4
P2860
Loss of Lean Body Mass as an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Loss of Lean Body Mass as an I ...... emotherapy for Gastric Cancer.
@en
Loss of Lean Body Mass as an I ...... emotherapy for Gastric Cancer.
@nl
type
label
Loss of Lean Body Mass as an I ...... emotherapy for Gastric Cancer.
@en
Loss of Lean Body Mass as an I ...... emotherapy for Gastric Cancer.
@nl
prefLabel
Loss of Lean Body Mass as an I ...... emotherapy for Gastric Cancer.
@en
Loss of Lean Body Mass as an I ...... emotherapy for Gastric Cancer.
@nl
P2093
P2860
P1476
Loss of Lean Body Mass as an I ...... emotherapy for Gastric Cancer.
@en
P2093
Haruhiko Cho
Hirohito Fujikawa
Kazuhito Tsuchida
Munetaka Masuda
Norio Yukawa
Taiichi Kawabe
Takaki Yoshikawa
Takanobu Yamada
Takashi Ogata
Takashi Oshima
P2860
P2888
P304
P356
10.1245/S10434-014-4296-Z
P577
2014-12-17T00:00:00Z
P5875
P6179
1027893641